Eli Lilly Launches Website for Community Oncologists

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 2
Volume 10
Issue 2

INDIANAPOLIS-Eli Lilly and Company has launched a new website for community medical oncologists and their staffs. The site, located at www.lillydirect.com, is designed to save oncology health care professionals time by streamlining many of their business-related responsibilities.

INDIANAPOLIS—Eli Lilly and Company has launched a new website for community medical oncologists and their staffs. The site, located at www.lillydirect.com, is designed to save oncology health care professionals time by streamlining many of their business-related responsibilities.

For example, using the new website, physicians can access several major wholesale distributors of oncology products at one time to place orders for chemotherapeutic agents.

Other features of the website include reimbursement assistance, patient messaging, medical information on Lilly oncology products, and links to information on Lilly and non-Lilly oncology clinical trials, publications, scientific meetings, and cooperative groups and associations.

Articles in this issue
Activated T Cells Can Alter Behavior of Leukemic B Cells
Response Continues for at Least 8 Months with Ibritumomab Tiuxetan
Chemotherapy Without Methotrexate Achieves Superb Results in Children With NHL
Iodine I 131 Tositumomab Induces Response in 70% of Patients Progressing After Rituximab
Synthetic Anthracycline Produces High Response Rates in SCLC
Ibritumomab Tiuxetan Produces 73% Response Rate in B-cell NHL
Rituximab Produces Clinical Responses in Even Steroid-Refractory Idiopathic Thrombocytopenic Purpura
G-CSF Might Prolong Rituximab Responses in NHL
Use of CAD Increases the Early Detection of Breast Cancer by 20%
Rituximab Plus Fludarabine May Be Good Alternative to Rituximab Plus CHOP
Student Cigarette Smoking Falls Significantly
Injectable COX-2 Inhibitor Effective in Postsurgery Pain
Patients’ Exercise Needs May Differ After Cancer Therapy
HAART Improves Survival in HIV-Positive NHL Patients
Liposomal Tretinoin Produces Impressive Responses in Refractory B-cell and T-cell Lymphomas

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
2 experts in this video
2 experts in this video
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Related Content
Biomarker analyses indicate the predictive potential of a 15-protein signature related to the efficacy of serplulimab plus chemotherapy in ES-SCLC.

Serplulimab Yields Sustained OS/PFS Benefits in Extensive-Stage SCLC

Russ Conroy
June 14th 2025
Article

Biomarker analyses indicate the predictive potential of a 15-protein signature related to the efficacy of serplulimab plus chemotherapy in ES-SCLC.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Results of a post hoc analysis found spleen and symptom response rates to be comparable with ESAs or danazol in combination with ruxolitinib for patients with myelofibrosis who have anemia.

Similar Splenic, Symptom Responses Are Reported With Ruxolitinib Combos in Myelofibrosis With Anemia

Ariana Pelosci
June 13th 2025
Article

Results of a post hoc analysis found spleen and symptom response rates to be comparable with ESAs or danazol in combination with ruxolitinib for patients with myelofibrosis who have anemia.

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging

Treatment with cyclosporin/cyclophosphamide following allogeneic stem cell transplant had improved efficacy vs cyclosporin/methotrexate in patients with high-risk hematologic cancers.

Cyclosporin/Cyclophosphamide Is a Potential New SOC in GVHD Management

Ariana Pelosci
June 13th 2025
Article

Treatment with cyclosporin/cyclophosphamide following allogeneic stem cell transplant had improved efficacy vs cyclosporin/methotrexate in patients with high-risk hematologic cancers.

Results from the phase 3 POD1UM-303/InterAACT-2 trial demonstrated improved PFS and OS in patients with locally recurrent or metastatic SCAC.

Adding Retifanlimab to Chemo Yields Clinical Benefit in Inoperable SCAC

Tim Cortese
June 13th 2025
Article

Results from the phase 3 POD1UM-303/InterAACT-2 trial demonstrated improved PFS and OS in patients with locally recurrent or metastatic SCAC.